About argenx
argenx news and updates
Argenx launches VYVGART
Argenx were well-prepared to launch VYVGART at the time of approval and are encouraged by the early response of the medical community, the engagement from patients, and the coverage decisions that have been made by payers.
Jan 1, 2022 | argenx.comArgenx launched Vyvgart on Jan 1st 22'.
As Argenx launched Vyvgart in early January, the biotech has yet to report any sales.
Jan 1, 2022 | biopharmadive.comArgenx receives financing of $700M
Dutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
Jan 1, 2022 | european-biotechnology.comArgenx goes public
Argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, raised $700 million in a secondary offering, the largest financing year-to-date for a rare disease drug developer.
Jan 1, 2022 | globalgenes.orgMedison group partners with Argenx
Medison Pharma has entered into a pact with the global immunology company Argenx to bring efgartigimod to market in Israel and across several European countries for treating adult patients with generalized myasthenia gravis (gMG).
Jan 1, 2022 | myastheniagravisnews.comArgenx hired Ana Cespedes as non-executive director to Board of Directors on Dec 12th 22'.
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors.
Dec 12, 2022 | bakersfield.comArgenx launches FcRn blocker Vyvgart
Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – for primary immune thrombocytopenia (ITP) – thanks to new data reported at the ASH annual meeting.
Dec 12, 2022 | pharmaphorum.com